Vaxxinity to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 04 2022 - 7:00AM
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the
development of a new class of immunotherapeutic vaccines, today
announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity,
will present at the Canaccord Genuity 42nd Annual Growth
Conference in Boston, MA on Thursday, August 11, 2022 at 1:00 p.m.
ET.
A live webcast of the presentation can be accessed under
“Events & Presentations” in the Investor section of the
Company’s website, https://ir.vaxxinity.com/events-presentations,
and will be available for replay for 90 days following the
event.
About Vaxxinity
Vaxxinity, Inc. is a purpose-driven biotechnology company
committed to democratizing healthcare across the globe. The company
is pioneering a new class of synthetic, peptide-based
immunotherapeutic vaccines aimed at disrupting the existing
treatment paradigm for chronic disease, increasingly dominated by
monoclonal antibodies, which suffer from prohibitive costs and
cumbersome administration. The company’s proprietary technology
platform has enabled the innovation of novel pipeline candidates
designed to bring the efficiency of vaccines to the treatment of
chronic diseases, including Alzheimer’s, Parkinson’s, migraine, and
hypercholesterolemia. The technology is also implemented as part of
a COVID-19 vaccine program. Vaxxinity has optimized its pipeline to
achieve a potentially historic, global impact on human health.
For more information about Vaxxinity, Inc., visit
http://www.vaxxinity.com and follow us on social media
@vaxxinity.
Forward-looking Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. The use of certain words, including "potentially," and "will"
and similar expressions, are intended to identify forward-looking
statements. These forward-looking statements involve substantial
risks and uncertainties, and are based on the current expectations
and assumptions of Vaxxinity’s management. Forward-looking
statements include statements about the development of a new class
of immunotherapeutic vaccines and the innovation and efficacy of
Vaxxinity’s product candidates. Various important factors could
cause actual results or events to differ materially from those that
may be expressed or implied by our forward-looking statements.
Additional important factors to be considered in connection with
forward-looking statements are described in the "Risk Factors"
section of the Company's Annual Report on Form 10-K filed with the
Securities and Exchange Commission on March 24, 2022 and other
reports we file with the Securities and Exchange Commission. The
forward-looking statements are made as of this date and Vaxxinity
does not undertake any obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
Investor ContactBen
Matonebenm@vaxxinity.com
Press ContactKaren
Chasemedia@vaxxinity.com
Vaxxinity (NASDAQ:VAXX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaxxinity (NASDAQ:VAXX)
Historical Stock Chart
From Sep 2023 to Sep 2024